Cancer Gene Therapy Market Analysis, Demand And Outlook 2025- 2034

Offering reliable and timely data, this report is a key resource for anyone building or refining their cancer gene therapy industry roadmap.

How Large Will The Cancer Gene Therapy Market Be By 2025?
The cancer gene therapy market size has grown rapidly in recent years. It will grow from $3.61 billion in 2024 to $4.21 billion in 2025 at a compound annual growth rate (CAGR) of 16.6%. The growth in the historic period can be attributed to growing awareness of oncovirus-related cancers, rising collaborations between biotech firms and academic institutions, increasing clinical trial activity in early-phase gene therapies, growing demand for ex vivo modified cell therapies, and a surge in strategic licensing agreements for gene therapy platforms.

The cancer gene therapy market size is expected to see rapid growth in the next few years. It will grow to $7.67 billion in 2029 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to rising focus on non-viral delivery systems, increasing availability of companion diagnostics, growing interest in off-the-shelf allogeneic cell therapies, rising expansion of contract development & manufacturing organizations (CDMOs), and advancing synthetic biology enabling customizable gene circuits. Major trends in the forecast period include advancement in non-viral gene delivery platforms, advanced manufacturing automation for gene therapy production, development of synthetic promoters for cancer-specific expression, innovation in intratumoral gene therapy administration, and development of multiplexed gene modulation strategies.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp

What Are Key Factors Driving The Demand In The Global Cancer Gene Therapy Market?
The increasing cancer incidence is expected to propel the growth of the cancer gene therapy market going forward. Cancer is a disease characterized by the uncontrolled multiplication of abnormal cells that can invade and spread to other parts of the body, arising in various tissues and organs and classified based on the cell or tissue type from which it originates. Cancer cases are increasing due to rising life expectancy, as the risk of developing cancer grows with age. Cancer gene therapy treats cancer by modifying or replacing faulty genes to stop cancer cell growth or enhance the immune system's ability to destroy them. For instance, in August 2024, Macmillan Cancer Support, a UK-based organization, reported that more than 3 million people in the UK are living with cancer. This figure is projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing cancer incidence is driving the growth of the cancer gene therapy market.

Comparative Analysis Of Leading Cancer Gene Therapy Market Segments
The cancer gene therapy market covered in this report is segmented

1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer
2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications
3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types
4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Diagnostic centers, Other End Users

Subsegments:
1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy
2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)
3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

What Are The Key Trends Shaping The Cancer Gene Therapy Industry?
Major companies operating in the cancer gene therapy market are focusing on developing advanced therapies, such as CAR-T cell therapy, to enhance treatment precision, improve patient outcomes, and target cancer cells more effectively while minimizing damage to healthy tissues. CAR-T therapy is an advanced immunotherapy where a patient’s immune cells are engineered to better detect and destroy cancer cells by adding special receptors to them. For instance, in April 2024, ImmunoACT, an India-based biotechnology company, launched NexCAR19 (actalycabtagene autoleucel), the country's first indigenously developed CAR-T cell therapy for cancer. Specifically designed to treat B-cell lymphomas and leukemias, NexCAR19 works by reprogramming a patient's own T cells to identify and destroy cancer cells. Based on advanced chimeric antigen receptor (CAR) technology, the therapy is locally manufactured, making it more affordable and accessible than imported alternatives. This launch marks a major milestone in India's entry into the global cancer gene therapy space, highlighting significant progress in domestic innovation and personalized cancer treatment.

Who Are The Prominent Players In The Cancer Gene Therapy Business?
Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, Biogen Inc., Sarepta Therapeutics Inc., AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, and Abeona Therapeutics Inc.

View the full cancer gene therapy market report here:
https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

Which Region Is Expected To Lead The Cancer Gene Therapy Market By 2025?
North America was the largest region in the cancer gene therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company